E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 11/10/2006 in the Prospect News Biotech Daily.

S&P rates Merck notes AA-

Standard & Poor's said it assigned AA- senior unsecured debt ratings to Merck & Co. Inc.'s $250 million senior-unsecured notes due 2011 and $500 million senior-unsecured notes due 2036 and affirmed the company's corporate credit and senior unsecured ratings at AA- and commercial paper rating at A-1+.

The outlook remains negative.

The agency said Merck's strong investment-grade ratings reflect the company's continued very diverse and profitable business profile, cash flow generation in excess of current needs and very conservative financial position and policies.

The ratings also incorporate Merck's challenge to revitalize its product pipeline and the uncertain magnitude and timing of Vioxx-related litigation, S&P added.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.